Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Condomines, Maud ^a   Arnason, Jon ^a   Benjamin, Reuben ^a   Gunset, Gertrude ^a   Plotkin, Jason ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIBODY; CD28 ANTIGEN; CD3 ZETA ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER INHIBITION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PATHOLOGY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD28; CTLA-4 ANTIGEN; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTORS, ANTIGEN; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938368102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130518     Document Type: Article

References (51)

1. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924. doi: 10.1200/JCO.2010.32.2537 PMID: 21282551
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733. doi: 10.1056/NEJMoa1103849 PMID: 21830940
3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720. doi: 10.1182/blood-2011-10-384388 PMID: 22160384
4. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra138.
5. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. (2014) Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med 6: 224ra225.
6. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9: 279-286. PMID: 12579196
7. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, et al. (2011) CARs on track in the clinic. Mol Ther 19: 432-438. doi: 10.1038/mt.2011.1 PMID: 21358705
8. Sadelain M, Riviere I, Brentjens R (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3: 35-45. PMID: 12509765
9. Gross G, Eshhar Z (1992) Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6: 3370-3378. PMID: 1464371
10. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1: 123-127. PMID: 10933046
11. Brocker T (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96: 1999-2001. PMID: 10961908
12. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826. doi: 10.1172/JCI46110 PMID: 21540550
13. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20: 70-75. PMID: 11753365
14. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-11004. PMID: 17108138
15. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, et al. (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13: 1440-1449. PMID: 18026115
16. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106: 3360-3365. doi: 10.1073/pnas.0813101106 PMID: 19211796
17. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18: 413-420. doi: 10.1038/mt.2009.210 PMID: 19773745
18. Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113. PMID: 14688315
19. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435. PMID: 17855649
20. Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229: 12-26. doi: 10.1111/j.1600-065X.2009.00770.x PMID: 19426212
21. Egen JG, Allison JP (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16: 23-35. PMID: 11825563
22. Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24: 65-97. PMID: 16551244
23. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410: 608-611. PMID: 11279502
24. Martin M, Schneider H, Azouz A, Rudd CE (2001) Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med 194: 1675-1681. PMID: 11733581
25. Chikuma S, Imboden JB, Bluestone JA (2003) Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 197: 129-135. PMID: 12515820
26. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. (2006) Reversal of the TCR stop signal by CTLA-4. Science 313: 1972-1975. PMID: 16931720
27. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603. doi: 10.1126/science.1202947 PMID: 21474713
28. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, et al. (2010) Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 33: 326-339. doi: 10.1016/j.immuni.2010.09.006 PMID: 20870175
29. Walker LS, Sansom DM (2015) Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 36: 63-70. doi: 10.1016/j.it.2014.12.001 PMID: 25582039
30. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164: 5319-5327. PMID: 10799894
31. Stumpf M, Zhou X, Chikuma S, Bluestone JA (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44: 1737-1746. doi: 10.1002/eji.201343891 PMID: 24648182
32. Markley JC, Sadelain M (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115: 3508-3519. doi: 10.1182/blood-2009-09-241398 PMID: 20190192
33. Gallardo HF, Tan C, Ory D, Sadelain M (1997) Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90: 952-957. PMID: 9242523
34. Ghani K, Wang X, de Campos-Lima PO, Olszewska M, Kamen A, Riviere I, et al. (2009) Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. Hum Gene Ther 20: 966-974. doi: 10.1089/hum.2009.001 PMID: 19453219
35. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, et al. (2005) Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65: 9080-9088. PMID: 16204083
36. Darlington PJ, Kirchhof MG, Criado G, Sondhi J, Madrenas J (2005) Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J Immunol 175: 996-1004. PMID: 16002699
37. Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, et al. (2012) Cutting edge: cell-extrinsic immune regulation by ctla-4 expressed on conventional T cells. J Immunol 189: 1118-1122. doi: 10.4049/jimmunol.1200972 PMID: 22753931
38. Corse E, Allison JP (2012) Cutting edge: ctla-4 on effector T cells inhibits in trans. J Immunol 189: 1123-1127. doi: 10.4049/jimmunol.1200695 PMID: 22753941
39. Gao JF, McIntyre MS, Juvet SC, Diao J, Li X, Vanama RB, et al. (2011) Regulation of antigen-expressing dendritic cells by double negative regulatory T cells. Eur J Immunol 41: 2699-2708. doi: 10.1002/eji.201141428 PMID: 21660936
40. Kowalczyk A, D'Souza CA, Zhang L (2014) Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3. Eur J Immunol 44: 1143-1155. doi: 10.1002/eji.201343601 PMID: 24338929
41. Wing JB, Ise W, Kurosaki T, Sakaguchi S (2014) Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41: 1013-1025. doi: 10.1016/j.immuni.2014.12.006 PMID: 25526312
42. Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, et al. (2014) Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function. Nat Immunol 15: 465-472. doi: 10.1038/ni. 2866 PMID: 24705298
43. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. (2010) Tumor-reactive CD4 (+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207: 637-650. doi: 10.1084/jem.20091918 PMID: 20156971
44. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105: 20410-20415. doi: 10.1073/pnas.0810114105 PMID: 19074257
45. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164. doi: 10.1016/S1470-2045(09)70334-1 PMID: 20004617
46. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, et al. (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6: 254ra128.
47. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, et al. (2011) Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 3: 80ra34.
48. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 363: 711-723. doi: 10.1056/NEJMoa1003466 PMID: 20525992
49. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: 2189-2199. doi: 10.1056/NEJMoa1406498 PMID: 25409260
50. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697. doi: 10.1200/JCO.2012.41.6750 PMID: 22614989
51. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine 18: 807-815. doi: 10.1038/nm.2700 PMID: 22466705